Brainsway is currently conducting a number of clinical trials in parallel to test the effectiveness of Deep TMS for treating several diseases. Brainsway Ltd. (TASE:BRIN) has obtained EU CE Mark certification to market its Deep TMS (transcranial magnetic stimulation) for the treatment of depression. Deep TMS has been developed to treat a range of neurological disorders by non-invasive therapy. In October 2008, Brainsway obtained CE Mark certification to market Deep TMS for the treatment of manic depression (bipolar disorder) in the EU following the success of a clinical trial for this indication.
Brainsway is currently conducting a number of clinical trials in parallel to test the effectiveness of Deep TMS for treating several diseases. In April, it announced a trial of the device to treat cocaine addition with the US National Institute on Drug Abuse, a unit of the National Institutes of Health. Yesterday, the company announced preliminary good interim results for Deep TMS for the treatment of Parkinson's disease conducted at Sheba Medical Center Tel Hashomer, in Israel.
Lire l'intégralité de l'article » (Source: article de Adi Ben-Israel @ Globes)
Anti Boycott Israel blog: maladie de Parkinson stimulation magnétique transcrânienne, addiction à la cocaïne, dépression
Brainsway sees good interim results in Parkinson's trial